Efficacy of selected treatments of HIV wasting: A systematic review and meta-analysis

Journal of Acquired Immune Deficiency Syndromes

Volumn 37, Issue SUPPL. 5, 2004, Pages

  Moyle, Graeme J ^a   Schoelles, Karen ^b   Fahrbach, Kyle ^b   Frame, Diana ^b   James, Kimberly ^b   Scheye, Rachel ^b   Cure Bolt, Nancy ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b MetaWorks Inc   (United States)

^c EMD SERONO INC   (United States)

Author keywords

Body composition; HIV wasting; Meta analysis; Physical function; Quality of life; Systematic review

Indexed keywords

ANABOLIC AGENT; HUMAN GROWTH HORMONE; PLACEBO; TESTOSTERONE;

BODY COMPOSITION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; LEAN BODY WEIGHT; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; WASTING SYNDROME; WORK CAPACITY;

ANABOLIC AGENTS; HIV WASTING SYNDROME; HUMAN GROWTH HORMONE; HUMANS; RECOMBINANT PROTEINS; TESTOSTERONE;

EID: 10044268408     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000144381.09350.5b     Document Type: Conference Paper

References (59)

1. Centers for Disease Control. Revision of the CDC surveillance case definition for the acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1987;36(Suppl 1):3S-15S.
2. Kotler DP, Tierney AR, Wang J, et al. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989;50:444-447.
3. Melchior JC, Niyongabo T, Henzel D, et al. Malnutrition and wasting, immunodepression and chronic inflammation as independent predictors of survival in HIV-infected patients. Nutrition. 1999;15:865-869.
4. Guenter P, Muurahainen N, Simons G, et al. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acquir Immune Defic Syndr. 1993;6:1130-1138.
5. Palenicek JP, Graham NM, He YD, et al. Weight loss prior to clinical AIDS as a predictor of survival. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:366-373.
6. Tang AM, Forrester J, Spiegelman D, et al. Weight loss and survival in HIV positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:230-236.
7. Grinspoon S, Mulligan K, for the Department of Health and Human Services Working Group on the Prevention and Treatment of Wasting and Weight Loss. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36(Suppl 2):S69-S78.
8. Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis and treatment. AIDS Patient Care STDS. 2001;15:411-423.
9. Wheeler DA, Gibert CL, Launer CA, et al. Weight loss as a predictor of survival and disease progression in HIV infection. J Acquir Immune Defic Syndr. 1998;18:80-85.
10. Testa MA, Lenderking WR. The impact of AIDS-associated wasting on quality of life: qualitative issues of measurement and evaluation. J Nutr. 1999;129(Suppl 1S):S282-S289.
11. Wilson IB, Roubenoff R, Knox TA, et al. Relation of lean body mass to health-related quality of life in persons with HIV. J Acquir Immune Defic Syndr. 2000;24:137-146.
12. Wanke CA, Silva M, Knox TA, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;31:803-805.
13. Dworkin MS, Williamson JM. AIDS wasting syndrome: trends, influence on opportunistic infections and survival. J Acquir Immune Defic Syndr. 2003;33:267-273.
14. Kotler DP, Grunfeld C. Pathophysiology and treatment of the AIDS wasting syndrome. AIDS Clin Rev. 1995;96:229-275.
15. Corcoran C, Grinspoon S. Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1999;340:1740-1750.
16. Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc. 2000;75:386-394.
17. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med. 1997;126:376-380.
18. Alderson P, Green S, Higgins JPT, eds. Cochrane Collaboration Handbook 4.2.1 [updated March 2004]. In: The Cochrane Library. Issue 2. Chichester, UK: John Wiley & Sons, Ltd.; 2004.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
20. Hedges L, Olkin I. Statistical Methods for Meta-Analysis. Orlando, FL: Academic Press: 1985:230-257.
21. Mwamburi MD, Gerrior J, Skully E, et al. International AIDS Society. XIV International AIDS Conference. Barcelona, Spain; July 7-12, 2002. Available at: http://www.ias.se/abstract/show.asp?abstract_id=4858. Accessed December 8, 2003.
22. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
23. Miller K, Corcoran C, Armstrong C, et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab. 1998;83:2717-2725.
24. Bhasin S, Storer TW, Javanbekht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA. 2000;283:763-770.
25. Dobs AS, Cofrancesco J, Nolten J, et al. The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med. 1999;107:126-132.
26. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;129:18-26.
27. Strawford A, Barbieri T, Neese R, et al. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:137-146.
28. Grinspoon S, Corcoran C, Parlman K, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting: a randomized, controlled trial. Ann Intern Med. 2000;133:348-355.
29. Moyle G, Daar ES, Gertner JM, et al. Growth hormone improves lean body mass, physical performance and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;35:367-375.
30. Strawford A, Barbieri T, Van Loan M, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial. JAMA. 1999;281:1282-1290,
31. Batterham MJ, Garsia R. A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. Int J Androl. 2001;24:232-240.
32. Jager H, Knechten H, Moll A, et al. Treatment of HIV-associated wasting with recombinant human growth hormone: monitoring of body composition changes by bioelectrical impedance analysis (BIA). Eur J Med Res. 2002;7:103-108.
33. Lee PD, Pivarnik JM, Bukar JG, et al. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab. 1996;81:2968-2975.
34. Waters D, Danska J, Hardy K, et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;125:865-872.
35. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Ann Intern Med. 1996;125:873-882.
36. Bolanowski M, Nilsson BE. Assessment of human body composition using dual-energy x-ray absorptiometry and bioelectrical impedance analysis. Med Sci Monit. 2001;7:1029-1033.
37. Cella DF, Von Roenn J, Lloyd S, et al. The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI): a brief assessment of patients' subjective response to treatment for anorexia/cachexia. Qual Life Res. 1995;4:221-231.
38. Bozzette SA, Hays RD, Berry SH, et al. Derivation and properties of a brief health status assessment instrument for use in HIV disease. J Acquir Immune Defic Syndr Hum Retroviral. 1995;8:253-265.
39. Berry SH, Bozzette SA, Hays RD, et al. Measuring Patient-Reported Health Status in Advanced HIV Disease: HIV-PARSE Instrument. Santa Monica, CA: RAND; 1994.
40. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care. 1992;29:786-798.
41. Hays RD, Cunningham WE, Ettl WK, et al. Health-related quality of life in HIV disease. Assessment. 1995;2:363-380.
42. Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weightless. AIDS. 1997;11:1347-1352.
43. RAND. Scoring Manual. Adult Health Status and Patient Satisfaction Measures Used in RAND's Health Insurance Experiment. Santa Monica, CA: RAND, 1988.
44. EUROQOL Group. EUROQOL: a new facility for the measurement of health-related quality of life. Health Policy (New York). 1990;16:199-200.
45. Watts RJ. Sexual function, health beliefs, and compliance with high blood pressure medications. Nurs Res. 1982;31:278-283.
46. Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med. 1994;121:400-408.
47. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8:77-100.
48. Grinspoon S, Corcoran C, Stanley T, et al. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab. 2000;85:60-65.
49. Health Sciences RAND. 36-Item Health Survey 1.0. Santa Monica, CA: RAND; 1992.
50. Earthman CP, Reid PM, Harper IT, et al. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. J Parenter Enteral Nutr. 2002;26:357-364.
51. Cella DF, McCain NL, Peterman AH, et al. Development and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res. 1996;5:450-463.
52. Gold J, High HA, Li Y, et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS. 1996;10:745-752.
53. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
54. Hengge UR, Stocks K, Wiehler H, et al. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS. 2003;17:699-710.
55. McNurlan MA, Garlick PJ, Steigbigel RT, et al. Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease. J Clin Invest. 1997;100:2125-2132.
56. Shikuma CM, Zackin R, Mildvan D, et al. Short-term effect of baseline CD4 and HIV-1 RNA on lean body mass gain following highly active antiretroviral therapy. Lipodystrophy. 2003;98:L67.
57. Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis. 2002;2:692-699.
58. Centers for Disease Control and Prevention. Cases of HIV infection and AIDS in the United States, by race/ethnicity, 1998-2002. HIV/AIDS Surveillance Supplemental Report; 10(No. 1):1-38. Available at: http://www.cdc.gov/hiv/stats/ hasrlink.htm. Accessed June 10, 2004.
59. Dolan S, Wilkie S, Aliabadi N, et al. Effects of testosterone administration in human immunodeficiency virus-infected women with low weight. Arch Intern Med. 2004;164:897-904.